EP4153181A1 — Pharmaceutical compositions comprising bictegravir
Assigned to Gilead Sciences Inc · Expires 2023-03-29 · 3y expired
What this patent protects
The present invention provides pharmaceutical compositions comprising an HIV integrase strand transfer inhibitor (e.g., bictegravir), or a pharmaceutically acceptable salt thereof, and methods of treating or preventing HIV in a subject comprising administering to the subject a th…
USPTO Abstract
The present invention provides pharmaceutical compositions comprising an HIV integrase strand transfer inhibitor (e.g., bictegravir), or a pharmaceutically acceptable salt thereof, and methods of treating or preventing HIV in a subject comprising administering to the subject a therapeutically effective amount of said pharmaceutical composition by injection, optionally in combination with one or more other therapeutic agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.